Fluarix Tetra 2025/2026 NH 0.5ml Vaccine

Fluarix Tetra 2025/2026 NH 0.5ml Vaccine is a quadrivalent inactivated influenza vaccine formulated for active immunization against influenza A and B virus types. This vaccine is designed to stimulate the immune system to produce antibodies, thereby providing protection against seasonal influenza and swine flu.

The vaccine is indicated for adults and children from 6 months of age, particularly those identified as being at high risk of developing influenza complications. This includes the elderly, pregnant women, and individuals with chronic health conditions such as diabetes, heart failure, kidney failure, or chronic obstructive pulmonary disease (COPD). Each 0.5ml dose is administered as an intramuscular injection.

Fluarix Tetra 2025/2026 NH 0.5ml Vaccine must be stored under cold-chain conditions, specifically refrigerated between +2°C and +8°C (36°F to 46°F), and must not be frozen. It is recommended to store the vaccine in its original packaging to protect it from light. This vaccine complies with the World Health Organisation (WHO) recommendation for the 2025/2026 Northern Hemisphere influenza season.

Key Features : 

Provides active immunization against two influenza A virus subtypes and two influenza B virus types for the 2025/2026 Northern Hemisphere season, indicated for individuals from 6 months of age.
Requires cold-chain storage at temperatures between +2°C and +8°C (36°F to 46°F), with strict instruction not to freeze.
Administered via intramuscular injection, typically as a single 0.5ml dose annually, with a two-dose schedule for previously unvaccinated children aged less than 9 years.
Complies with the World Health Organisation (WHO) recommendation for the 2025/2026 Northern Hemisphere influenza season.